The
View from Here
Adriaan A. Lammertsma
The value of in vivo imaging studies in drug development has long been recognised, but only in recent years it seems to become incorporated on a more routine basis...
Read
more...
Upcoming
Issues
Issue
7/July '06
Drug Metabolism
Issue 8/August '06
RNAi for target discovery and validation
Issue 9/September '06
R&D Strategy
|
|
|
| |
Top Reviews
|
|
Using imaging biomarkers to accelerate drug development and clinical trials
Pien HH et al.
Drug Discovery Today
There is increasing evidence that human medical imaging can help answer key
questions that arise during the drug development process. Imaging modalities such
as magnetic resonance imaging, computed tomography and positron emission
tomography can offer significant insights into the bioactivity, pharmacokinetics and
dosing of drugs, in addition to supporting registration applications...
|
|
Imaging addiction with PET: is insight in sight?
Schiffer WK et al.
Drug Discovery Today
Neurochemical imaging studies can identify molecular targets of abused drugs and link them to the underlying pathology associated with behaviors such as drug dependence, addiction and withdrawal. positron emission tomography (PET) is opening new avenues for the investigation of the neurochemical disturbances underlying drug abuse and addiction and the in vivo mechanisms by which medications might ameliorate these conditions...
|
|
MRI-guided immunotherapy development for multiple sclerosis in a primate
't Hart BA et al.
Drug Discovery Today
Multiple sclerosis is a serious neurological disease that affects 1 in 1000 young adults in Europe and the USA. The development of an effective therapy for this enigmatic disease is plagued by the failure of many treatments to reproduce in patients the promising effects observed in animal models....
Click here to subscribe to Drug Discovery Today.
|
|
| |
Abstracts of Key Research Articles
Imaging Technologies
Lammertsma AA, ed.
Drug Discovery Today: Technologies 2005; 2(4): 303-304
A role for fMRI in optimizing CNS drug development
Borsook D, Becerra L, Hargreaves R.
Nat Rev Drug Discov. 2006; Apr 7; 5(5): 411-425
Molecular imaging in the development of cancer therapeutics
Czernin J, Weber WA, Herschman HR
Annu Rev Med. 2006; 57: 99-118
Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer
Hoekstra CJ et al.
J Clin Oncol 2005; Nov 20; 23(33): 8362-8370
Using positron emission tomography to facilitate CNS drug development
Lee CM, Farde L
Trends Pharmacol Sci. 2006; May 5; [Epub ahead of print].
Imaging biomarkers as surrogate endpoints for drug development
Richter WS
Eur J Nucl Med Mol Imaging. 2006; May 24; [Epub ahead of print].
Consensus Recommendations for the Use of 18F-FDG PET as an Indicator of Therapeutic Response in Patients in National Cancer Institute Trials
Shankar LK et al.
J Nucl Med. 2006; Jun; 47(6): 1059-1066
Antipsychotic drug action: targets for drug discovery with neurochemical imaging
Stone JM, Pilowsky LS
Expert Rev Neurother. 2006; Jan; 6(1): 57-64
The role of fMRI in drug discovery
Wise RG, Tracey I
J Magn Reson Imaging. 2006; Jun; 23(6): 862-76
Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies
Workman P et al.
J Natl Cancer Inst. 2006; May 3; 98(9): 580-98
|
|
RELATED
CONFERENCES
Hit to Lead 2006
2nd Annual Obesity Drug Development Summit
RELATED JOBS
Research Biologist / Pharmacologist
GE Healthcare
London, UK
[more
details]
Head of Proteomics
European Institute of Oncology
Milan, Italy
[more
details]
Senior Imaging Scientist
Boston Scientific
Marlborough, US
[more
details]
|
|
